Evolving patterns in a collaboration network of global R&D on monoclonal antibodies. Issue 7 (3rd October 2017)

• Record Type: Journal Article
• Authors: Kong, Xiangjun; Wan, Jian-bo; Hu, Hao; Su, Shibing; Hu, Yuanjia
• Is Part Of: MAbs. Volume 9:Issue 7(2017)
• Page Start: 1041
• Page End: 1051
• Publication Date: 2017-10-03
• Subjects: collaboration network -- dedicated biotechnology firms -- inter-organizational relationship -- mergers and acquisitions -- monoclonal antibodies -- network evolution -- R&D -- pharmaceutical companies -- technological innovation; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2017.1356527
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: We investigated the evolution process of collaborative inter-organizational network of the research and development (R&D) on monoclonal antibody (mAb) over the past 30 y. The annual detection of the collaboration network provides dynamics on network structures and relationship changes among different organizations. Our research showed continuous growth of the network's scale and complexity due to the constant entry of new organizations and the forging of new partnering relationships. The evolving topological features reveal a core-periphery structure that became clearer over time and an increasing heterogeneity within the collaborative mAb R&D network. As measured by the number of network participants, dedicated biotechnology firms (DBFs) were the dominant organization form in the field of mAb development, but their average centrality was reduced during the period of 2004–2009, when pharmaceutical companies took over the positions of DBFs. Along with the network evolution, 2 waves of substitution on the leading positions were driven by technological innovations and mergers and acquisitions (M&A). In addition, this study analyzed organizational-level behaviors to help understand the evolution of network structures over the field of mAb development across the different technologically innovative or economic contexts.